Defence


Cyclopharm breaks into US defence veterans market

Defence




Radiopharmaceutical system manufacturer Cyclopharm has entered into an agreement to supply the Veterans Health Administration (VA), the largest US government health care system, with the pharmaceutical and consumable components of its Technegas imaging system.

The Interim Agreement immediately provides the 120 Veterans Affairs hospitals, which have nuclear medicine departments, access to an agreed contract for these products.

This IA is the first step to Technegas’ inclusion on the broader US Federal Supply Schedule (FSS), the simplified procurement service for US federal agencies including the Department of Defense (DoD), Veterans Administration (VA), and Public Health Service (PHS) hospitals.

Cyclopharm CEO James McBrayer said: “Securing this Interim Agreement is critical for streamlining the United States federal government procurement process.

“This agreement bypasses the need for Cyclopharm to negotiate separate contracts with each of the 20 Regional Procurement Offices within the VA or potentially follow a reseller pathway that would delay the deployment of Technegas, distance us from our customers and impact margins beyond the legislated discounts required for federal contracts.”

Use of Technegas, an ultra-fine dispersion of the radiopharmaceutical Technetium-99m within a gas used in diagnostic functional lung imaging, was approved for sale in the US by the US Food and Drug Administration in October 2023.

McBrayer said: “Throughout this process, we have leveraged our commercial experience and success in the 65 other countries where Technegas is the preferred agent of choice.

“In these markets, complementary and evolving technologies are continually expanding Technegas’ indications for use in respiratory medicine.

“This direct VA agreement is evidence of the traction we continue to gain in the US, which is largest nuclear medicine market globally.”

In parallel with the IA covering the pharmaceutical component agreement, Cyclopharm is also progressing with the necessary registrations to include the Technegas System (pictured), the medical device component of Technegas, in the same streamlined process.

Cyclopharm also announced the receipt of its first purchase order for Technegas from a Department of Defense (DoD) hospital.

Further reading:
Cyclopharm’s Technegas approved for US market in sales milestone

Picture: Picture: University of Newcastle/Trial of Technegas generator



Share this Story
Defence



Stay Informed


Go to Top